Eiger BioPharmaceuticals, Inc.
EIGR
Peringkat dalam Saham
#36445
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Harga Saham
$1.73
Terakhir disinkronkan: 2025-06-17
Kapitalisasi Pasar
$2.55M
Perubahan (1 hari)
-0.29%
Perubahan (1 tahun)
-79.71%
Negara
US
Perdagangan Eiger BioPharmaceuticals, Inc. (EIGR)
Kategori
Healthcare
Laba untuk Eiger BioPharmaceuticals, Inc. (EIGR)
Laba pada Dec 2023 TTM: $-74.96M
Menurut laporan keuangan terbaru dari Eiger BioPharmaceuticals, Inc., laba saat ini perusahaan adalah $-74.96M. Pada tahun 2022, perusahaan memperoleh laba sebesar $-96.75M, penurunan dibandingkan dengan laba tahun 2021 sebesar $-33.85M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Eiger BioPharmaceuticals, Inc. dari 2016 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2026 (TTM) | $-74.96M | 0.00% |
| 2023 | $-74.96M | -22.53% |
| 2022 | $-96.75M | 185.80% |
| 2021 | $-33.85M | -47.96% |
| 2020 | $-65.05M | -7.40% |
| 2019 | $-70.25M | 34.09% |
| 2018 | $-52.39M | 23.42% |
| 2017 | $-42.45M | -9.85% |
| 2016 | $-47.09M | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| $5.27B | -7,137.23% |
US
|
|
| $-3.09B | 4,018.36% |
US
|
|
| $-4.02B | 5,258.00% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -2,702.36% |
NL
|
